Prostate cancer is the focus of the Sipuleucel-T (ProvengeTM) cancer vaccine, which is based on “immune cells” and uses an autologous entire immune cell population treated with PA2024 (a prostate antigen that contains prostatic acid phosphatase, or PAP) linked to GM CSF (granulocyte-macrophage colony-stimulating factor). Here, ACP3 is linked to prostate carcinoma.